Payment overview · 2025
General Payments
$2,613.65
114 reported records · 29 companies
Healthcare provider profile · identity verified
Raffi Calikyan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · JOHNSTON, RI · NPI 1417063603
Verified facts
What the public records show
CMS Open Payments records show Raffi Calikyan, M.D. received $2,613.65 in general payments during 2025 across 114 reported records.
GlaxoSmithKline, LLC. accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ofev, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 663 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $560.14 | 21.4% | 27 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $227.77 | 8.7% | 11 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $208.94 | 8.0% | 6 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $167.56 | 6.4% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $152.33 | 5.8% | 6 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $144.87 | 5.5% | 7 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $135.95 | 5.2% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $98.88 | 3.8% | 4 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $92.22 | 3.5% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $88.91 | 3.4% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $70.14 | 2.7% | 3 | 2025 |
| Inogen, Inc. | Unresolved — no canonical attribution shown | $67.11 | 2.6% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $65.81 | 2.5% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $63.98 | 2.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $56.78 | 2.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.64 | 2.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $54.87 | 2.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.62 | 1.7% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $41.09 | 1.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.73 | 1.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.81 | 1.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $24.64 | 0.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.70 | 0.9% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $21.79 | 0.8% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $19.63 | 0.8% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.00 | 0.7% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.77 | 0.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.46 | 0.7% | 1 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $13.51 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,613.65 | 114 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $344.89 | 12 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $263.15 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $253.70 | 15 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $167.56 | 8 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $144.87 | 7 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $129.42 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $110.12 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $98.88 | 4 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $92.22 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $88.91 | 4 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $70.14 | 3 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $67.49 | 3 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | Inogen, Inc. | $67.11 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $65.81 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $64.36 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $63.98 | 3 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $61.60 | 2 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $56.78 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.64 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $54.87 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.16 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.62 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.62 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.62 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $43.29 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $43.29 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.73 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OFEV ofev |
2025 | Ofev | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 663 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
663 | 118 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 663 | 118 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 567 | 158 |
| Ventolin Hfa | Albuterol Sulfate | 225 | 69 |
| Breo Ellipta | Fluticasone/Vilanterol | 222 | 36 |
| Montelukast Sodium | Montelukast Sodium | 210 | 50 |
| Prednisone | Prednisone | 198 | 102 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 172 | 39 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 169 | 25 |
| Furosemide | Furosemide | 158 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 144 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 55 |
| Gabapentin | Gabapentin | 109 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 100 | 27 |
| Omeprazole | Omeprazole | 88 | 27 |
| Spiriva Respimat | Tiotropium Bromide | 87 | 31 |
| Losartan Potassium | Losartan Potassium | 86 | 24 |
| Lisinopril | Lisinopril | 81 | 20 |
| Alprazolam | Alprazolam | 78 | 15 |
| Eliquis | Apixaban | 76 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 18 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 66 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 63 | 18 |
| Incruse Ellipta | Umeclidinium Bromide | 59 | suppressed |
| Roflumilast | Roflumilast | 58 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | 15 |
| Simvastatin | Simvastatin | 52 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 51 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 50 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 48 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 18 |
| Levofloxacin | Levofloxacin | 44 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 13 |
| Metformin Hcl | Metformin Hcl | 43 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 43 | 15 |
| Azithromycin | Azithromycin | 40 | 33 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Potassium Chloride | Potassium Chloride | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 27 |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Ofev | Nintedanib Esylate | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,613.65 · 114 records | GlaxoSmithKline, LLC. | ABRYSVO, ACTHAR, AIRSUPRA, AMVUTTRA, AREXVY, Arikayce, BREZTRI, COMIRNATY, Cologuard Collection Kit, DUPIXENT, Dexcom G6 Transmitter, FASENRA, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JASCAYD, Kerendia, NUCALA, OFEV, OPSUMIT, Ohtuvayre, PREVNAR 20, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, QULIPTA, REXULTI, SHINGRIX, TELEPATCH CARDIAC MONITOR, TEZSPIRE, TRELEGY ELLIPTA, UBRELVY, UPTRAVI, VOQUEZNA, Vest Therapy Und, WAKIX, XYOSTED, YUPELRI, ZERBAXA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ofev play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error